Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio (NASDAQ: MBIO) has successfully regained compliance with all Nasdaq Capital Market listing requirements, as announced on March 05, 2025. The company received formal confirmation from Nasdaq on February 26, 2025, that it has met the minimum stockholders' equity requirement under Listing Rule 5550(b)(1). Additionally, Mustang had previously regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). With both compliance matters now resolved, the company maintains its continued listing status on the Nasdaq Capital Market.
Mustang Bio (NASDAQ: MBIO) ha ripristinato con successo la conformità a tutti i requisiti di quotazione del Nasdaq Capital Market, come annunciato il 5 marzo 2025. L'azienda ha ricevuto conferma formale dal Nasdaq il 26 febbraio 2025, di aver soddisfatto il requisito minimo di patrimonio netto degli azionisti ai sensi della Regola di Quotazione 5550(b)(1). Inoltre, Mustang aveva precedentemente ripristinato la conformità al requisito del prezzo minimo di offerta ai sensi della Regola di Quotazione 5550(a)(2) del Nasdaq. Con entrambe le questioni di conformità ora risolte, l'azienda mantiene il suo stato di quotazione continua sul Nasdaq Capital Market.
Mustang Bio (NASDAQ: MBIO) ha recuperado con éxito el cumplimiento de todos los requisitos de cotización del Nasdaq Capital Market, como se anunció el 5 de marzo de 2025. La empresa recibió confirmación formal de Nasdaq el 26 de febrero de 2025, de que ha cumplido con el requisito mínimo de capital de los accionistas bajo la Regla de Cotización 5550(b)(1). Además, Mustang había recuperado anteriormente el cumplimiento del requisito de precio mínimo de oferta bajo la Regla de Cotización 5550(a)(2) de Nasdaq. Con ambas cuestiones de cumplimiento ahora resueltas, la empresa mantiene su estado de cotización continua en el Nasdaq Capital Market.
머스탱 바이오 (NASDAQ: MBIO)는 2025년 3월 5일 발표된 바와 같이 Nasdaq 자본 시장의 모든 상장 요구 사항을 성공적으로 준수했습니다. 회사는 2025년 2월 26일 Nasdaq로부터 주주 자본의 최소 요건을 충족했다는 공식 확인을 받았습니다. 또한, 머스탱은 Nasdaq 상장 규칙 5550(a)(2)에 따른 최소 입찰 가격 요건을 이전에 충족했습니다. 두 가지 준수 문제가 모두 해결됨에 따라, 회사는 Nasdaq 자본 시장에서 계속 상장 상태를 유지합니다.
Mustang Bio (NASDAQ: MBIO) a réussi à retrouver la conformité avec toutes les exigences de cotation du Nasdaq Capital Market, comme annoncé le 5 mars 2025. L'entreprise a reçu une confirmation formelle de Nasdaq le 26 février 2025, qu'elle a satisfait à l'exigence minimale de capitaux propres des actionnaires conformément à la Règle de Cotation 5550(b)(1). De plus, Mustang avait précédemment retrouvé la conformité avec l'exigence de prix d'offre minimum selon la Règle de Cotation 5550(a)(2) de Nasdaq. Avec la résolution de ces deux questions de conformité, l'entreprise maintient son statut de cotation continue sur le Nasdaq Capital Market.
Mustang Bio (NASDAQ: MBIO) hat erfolgreich die Einhaltung aller Anforderungen für die Notierung am Nasdaq Capital Market wiederhergestellt, wie am 5. März 2025 bekannt gegeben. Das Unternehmen erhielt am 26. Februar 2025 eine formelle Bestätigung von Nasdaq, dass es die Mindestanforderung an das Eigenkapital der Aktionäre gemäß der Notierungsregel 5550(b)(1) erfüllt hat. Darüber hinaus hatte Mustang zuvor die Einhaltung der Mindestgebotsanforderung gemäß der Notierungsregel 5550(a)(2) von Nasdaq wiederhergestellt. Mit der Lösung beider Compliance-Angelegenheiten behält das Unternehmen seinen fortlaufenden Notierungsstatus am Nasdaq Capital Market bei.
- Regained full Nasdaq listing compliance
- Meets minimum stockholders' equity requirement
- Maintains Nasdaq Capital Market listing status
- None.
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. Therefore, Mustang now meets all Nasdaq Capital Market listing requirements for continued listing, and the matters are now closed.
About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies. Mustang’s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the SEC. Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. The Company’s forward-looking statements, include, but are not limited to, statements regarding the Company’s future compliance with Nasdaq’s continued listing requirements, any statements relating to our growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as investigational new drug (IND) applications and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties. Risks and uncertainties include, among other things, our need for substantial additional funds in the near future; risks that any actual or potential clinical trials may not initiate or complete in sufficient timeframes to advance the Company’s corporate objectives, or at all, or that any promising early results obtained therefrom may not be replicable; disruption from the sale of the Company’s manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of Company announcements on the market price of the Company’s common stock; the development stage of the Company’s primary product candidates; the Company’s ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; government regulation; patent and intellectual property matters; competition; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K filed on March 11, 2024, subsequent Quarterly Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contacts:
Jaclyn Jaffe and Nicole McCloskey
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com
FAQ
When did Mustang Bio (MBIO) regain Nasdaq compliance in 2025?
What Nasdaq requirements did Mustang Bio (MBIO) meet in 2025?
Is Mustang Bio (MBIO) still listed on Nasdaq Capital Market?
What is the significance of Mustang Bio's Nasdaq compliance for investors?
